Estelle Lecluze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Estelle Lecluze has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Pincez
Division of Pediatric Hematology‐Oncology CHU Sainte‐Justine Montreal Quebec Canada
5 shared publications - Guillaume Lettre
Université de Montréal
3 shared publications - Amanda Bell Grimes
Texas Children's Cancer and Hematology Center Texas Children's Hospital Houston Texas USA
2 shared publications - Manon Saby
CHU Sainte-Justine Azrieli Research Center, Montréal, QC H3T 1C5, Canada
2 shared publications - Stennio Da Silva Faria
CHU Sainte-Justine Azrieli Research Center, Montreal, QC, Canada
2 shared publications Alexia Muresan
Collégial International Sainte‐Anne Montréal Canada
1 shared publication
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7251-7254
Clonal hematopoiesis in autoimmune hemolytic anemia
- 29 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7251-7254
Clonal hematopoiesis in autoimmune hemolytic anemia
- Open Access
- 11 September 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Estimating the effect of fetal hemoglobin on sickle cell trait using polygenic scores
- 11 September 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessEstimating the effect of fetal hemoglobin on sickle cell trait using polygenic scores
- Open Access
- 3 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Improvement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center
Background: Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure: We aimed to assess the impact of these changes on the evolution in the healthcare utilization (HCU) of children with SCD in a Canadian pediatric tertiary center from 2009 to 2024. Results: The number of children with SCD followed at our center more than doubled (221 to 499 patients). Practice changes reduced mean time to hydroxyurea introduction, resulting in a steady annual increase in mean fetal hemoglobin across the patients with HbSS. Reflecting the number of patients followed, the absolute number of annual outpatient and ED visits increased significantly (1207 to 1769 and 192 to 526, respectively). However, there was a significant decrease in the mean number of outpatient visits (5.46 to 3.55 [ p = 0.03]) and hospitalizations (1.18 to 0.58 [ p p <0.0001]). Conclusion: Although the number of patients with SCD followed at our institution drastically increased in 15 years, the practice changes were effective and likely mitigated the impact on admissions. It illustrates the significant impact of improved management in the care of patients with SCD. Allocated resources need to reflect the overall increase in HCU to allow for continuous optimal care of this vulnerable population.
- 3 August 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Open AccessImprovement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center
Background: Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure: We aimed to assess the impact of these changes on the evolution in the healthcare utilization (HCU) of children with SCD in a Canadian pediatric tertiary center from 2009 to 2024. Results: The number of children with SCD followed at our center more than doubled (221 to 499 patients). Practice changes reduced mean time to hydroxyurea introduction, resulting in a steady annual increase in mean fetal hemoglobin across the patients with HbSS. Reflecting the number of patients followed, the absolute number of annual outpatient and ED visits increased significantly (1207 to 1769 and 192 to 526, respectively). However, there was a significant decrease in the mean number of outpatient visits (5.46 to 3.55 [ p = 0.03]) and hospitalizations (1.18 to 0.58 [ p p <0.0001]). Conclusion: Although the number of patients with SCD followed at our institution drastically increased in 15 years, the practice changes were effective and likely mitigated the impact on admissions. It illustrates the significant impact of improved management in the care of patients with SCD. Allocated resources need to reflect the overall increase in HCU to allow for continuous optimal care of this vulnerable population.
- Open Access
- 11 September 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (4)
Ubiquitous dysregulation of the Wnt pathway in immune thrombocytopenia genetic susceptibility
- 11 September 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (4)
Open AccessUbiquitous dysregulation of the Wnt pathway in immune thrombocytopenia genetic susceptibility
- Open Access
- 13 July 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (12) , 1888-1897
Association Analyses of Predicted Loss-of-Function Variants Prioritized 15 Genes as Blood Pressure Regulators
- 13 July 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (12) , 1888-1897
Open AccessAssociation Analyses of Predicted Loss-of-Function Variants Prioritized 15 Genes as Blood Pressure Regulators
- Open Access
- 12 July 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (12) , 1888-1897
Association Analyses of Predicted Loss-of-Function Variants Prioritized 15 Genes as Blood Pressure Regulators
- 12 July 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (12) , 1888-1897
Open AccessAssociation Analyses of Predicted Loss-of-Function Variants Prioritized 15 Genes as Blood Pressure Regulators
- Open Access
Association analyses of predicted loss-of-function variants prioritized 15 genes as blood pressure regulators
Background: Hypertension, clinically defined by elevated blood pressure (BP), is an important cause of mortality and morbidity worldwide. Many risk factors for hypertension are known, including a positive family history, which suggests that genetics contribute to inter-individual BP variation. Genome-wide association studies (GWAS) have identified >1000 loci associated with BP, yet the identity of the genes responsible for these associations remains largely unknown. Methods: To pinpoint genes that causally impact BP variation in humans, we analyzed predicted loss-of-function (pLoF) variants in the UK Biobank whole-exome sequencing dataset (n=454,709 participants, 6% non-European ancestry). We analyzed genetic associations between systolic or diastolic BP (SBP/DBP) and single pLoF variants (additive and recessive genetic models) as well as with the burden of very rare pLoF variants (minor allele frequency [MAF] ANKDD1B , ENPEP , PNCK, BTN3A2, C1orf145 [OBSCN-AS1] , CASP9 , DBH , KIAA1161 [MYORG] , OR4X1 , and TMC3 ). We also found a burden of rare pLoF variants in five additional genes associated with BP ( TTN, NOS3, FES, SMAD6, COL21A1 ). Except for PNCK , which is located on the X-chromosome, these genes map near variants previously associated with BP by GWAS, validating the study of pLoF variants to prioritize causal genes at GWAS loci. Conclusions: Our study highlights 15 genes that likely modulate BP in humans, including five genes that harbor pLoF variants associated with lower BP.
Open AccessAssociation analyses of predicted loss-of-function variants prioritized 15 genes as blood pressure regulators
Background: Hypertension, clinically defined by elevated blood pressure (BP), is an important cause of mortality and morbidity worldwide. Many risk factors for hypertension are known, including a positive family history, which suggests that genetics contribute to inter-individual BP variation. Genome-wide association studies (GWAS) have identified >1000 loci associated with BP, yet the identity of the genes responsible for these associations remains largely unknown. Methods: To pinpoint genes that causally impact BP variation in humans, we analyzed predicted loss-of-function (pLoF) variants in the UK Biobank whole-exome sequencing dataset (n=454,709 participants, 6% non-European ancestry). We analyzed genetic associations between systolic or diastolic BP (SBP/DBP) and single pLoF variants (additive and recessive genetic models) as well as with the burden of very rare pLoF variants (minor allele frequency [MAF] ANKDD1B , ENPEP , PNCK, BTN3A2, C1orf145 [OBSCN-AS1] , CASP9 , DBH , KIAA1161 [MYORG] , OR4X1 , and TMC3 ). We also found a burden of rare pLoF variants in five additional genes associated with BP ( TTN, NOS3, FES, SMAD6, COL21A1 ). Except for PNCK , which is located on the X-chromosome, these genes map near variants previously associated with BP by GWAS, validating the study of pLoF variants to prioritize causal genes at GWAS loci. Conclusions: Our study highlights 15 genes that likely modulate BP in humans, including five genes that harbor pLoF variants associated with lower BP.